SB 385 (The Vax Act) requires Maryland’s Secretary of Health to issue evidence-based recommendations for immunizations, screenings, and preventive services, aligning with guidance from major medical organizations like the CDC and U.S. Preventive Services Task Force. It expands pharmacists’ authority to administer vaccines (including those recommended by CDC or the Secretary) to patients aged 3+ after completing specific training and certification, while mandating health insurers to cover these services without cost-sharing. The bill also repeals outdated pertussis-related provisions and updates reporting requirements for pharmacists. This directly affects pharmacists, health insurers, and patients seeking preventive care, aiming to improve access to vaccinations and screenings.
HB 637 ("The Vax Act") requires Maryland's Secretary of Health to issue science-based recommendations for immunizations, screenings, and preventive services using guidance from major medical organizations like the CDC and American Academy of Pediatrics. It expands pharmacists' authority to administer flu, COVID-19, and emergency vaccines to patients aged 3 and older (previously limited to 18+ for some vaccines) after completing specific training. The bill also mandates that health insurance plans cover these recommended services without cost-sharing for patients. This directly affects pharmacists, health insurers, and Maryland residents seeking preventive care, particularly children and adults needing routine vaccinations.
HB 498 removes an existing exemption that allowed intermediate care facilities providing substance use disorder treatment to change bed capacity without a certificate of need. It specifically targets facilities offering "medically managed residential substance use disorder treatment services," requiring them to file 45 days' written notice with the health commission before operating or expanding. The commission must then review and approve these changes based on whether they align with the state health plan, improve service efficiency, and serve the public interest. This bill directly affects facilities providing residential substance use treatment by adding a review process for bed capacity changes or new operations, replacing the previous exemption.
This bill requires health insurers and health plans in Maryland to cover salpingectomy (surgery to remove fallopian tubes) specifically for ovarian cancer prevention as a standard benefit, with no out-of-pocket costs like copays or deductibles for patients. It applies to all health insurance policies issued in Maryland after January 1, 2027, directly affecting women who might choose this preventive surgery and the insurers providing coverage. The key provision bans cost-sharing for this procedure, except when an individual is enrolled in a high-deductible health plan meeting federal criteria. This ensures access to a proven preventive measure without financial barriers for most patients.
SB 866 requires chain restaurants with 20 or more locations in Maryland to display warning icons next to menu items exceeding 1,150mg sodium or 25mg added sugars per serving, starting January 1, 2028. The Maryland Department of Health must create these icons and guidelines by January 1, 2027, and run a public education campaign during 2027 to explain compliance. The bill directly affects large chain restaurants by mandating clear labeling of high-sodium and high-sugar menu items. It defines "high sodium" as 1,150mg per serving and "high added sugars" as 25mg per serving for labeling purposes.
HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
HB 494 requires health insurance companies, nonprofit health service plans, and health maintenance organizations (HMOs) operating in Maryland to structure their reimbursements to primary care providers in a way that meets annual investment targets set by the state. Starting February 1, 2026, these entities must report their progress toward meeting these targets when filing new or updated premium rates with the Maryland Insurance Commissioner. The bill amends insurance code sections to mandate this reporting requirement as part of premium rate filings. It takes effect October 1, 2026, focusing on transparency and accountability for primary care funding.
HB 598 creates a temporary license for internationally trained physicians to practice medicine in Maryland under specific conditions. It allows the State Board of Physicians to issue a 3-year license (non-renewable) to doctors who hold a WHO-recognized medical degree outside the U.S., completed 2 years of equivalent postgraduate training, practiced medicine for 5 of the last 7 years abroad, passed U.S. medical exams (USMLE Steps 1-3), and meet other criteria like English proficiency and Maryland residency. The license requires physicians to pursue full licensure through board-established pathways after the temporary period ends. This directly affects internationally trained doctors seeking to work in Maryland’s healthcare system, providing a structured but limited pathway to practice.
HB 633 requires Maryland health insurers, nonprofit health plans, and health maintenance organizations to cover salpingectomy (surgical removal of fallopian tubes) as a preventive measure for ovarian cancer. It prohibits these insurers from charging copayments, coinsurance, or deductibles for this specific procedure, ensuring no out-of-pocket costs for covered individuals. The exception applies only to high-deductible health plans under federal law, allowing the deductible to apply to the procedure in those cases. This law directly affects women eligible for preventive care and the health insurance providers operating in Maryland.
SB 489 modifies Maryland's licensing rules for physicians trained at international medical schools. It exempts applicants who provide evidence of completing two years of postgraduate training accredited by ACGME-I or another board-recognized body from standard educational requirements. These physicians would be permitted to practice medicine only during their initial license term under mandatory supervision, as specified by the Board. The bill takes effect October 1, 2026, directly affecting international medical graduates meeting these specific training criteria.
